Tao Zhang
Second Hospital of Tianjin Medical University(CN)Liaoning Cancer Hospital & Institute(CN)Tianjin Medical University(CN)
Publications by Year
Research Areas
Cancer-related molecular mechanisms research, RNA modifications and cancer, Ferroptosis and cancer prognosis, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial(2023)380 cited
- → Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer(2021)246 cited
- → Correction to: Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer(2022)241 cited
- → lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis(2020)177 cited
- → Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial